Lori Kagy, MD
Allergy & Immunology · Little Rock, ARNPI 1598744625
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.6% of the total across 174 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by Sanofi at 31.3% of the total. That places this record below the midpoint for allergy & immunology clinicians in AR, where the typical reported total is $3,878.
Across 174 payments — averaging $20.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$1K
- GSK$920
- Regeneron Healthcare Solutions, Inc.$367
- AstraZeneca$205
- Genentech USA, Inc.$163
- Phadia US Inc.$150
- plus $679 from 16 others
What the payments were for
- Consulting fees$191%
- Food & beverage$3,52998%
- Education$662%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 40 | $1,130 |
| GSK | 64 | $920 |
| Regeneron Healthcare Solutions, Inc. | 15 | $367 |
| AstraZeneca | 12 | $205 |
| Genentech USA, Inc. | 9 | $163 |
| Phadia US Inc. | 1 | $150 |
| Novartis | 6 | $134 |
| Amgen | 5 | $97 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $61 |
| Lilly USA, LLC | 2 | $50 |
| Optinose US, Inc. | 3 | $45 |
| Blueprint Medicines Corporation | 1 | $44 |
| Biocryst US Sales Co., LLC | 2 | $43 |
| Pfizer | 2 | $36 |
| Kaleo, Inc. | 2 | $32 |
| Grifols USA, LLC | 1 | $25 |
| Pharming Healthcare, Inc. | 1 | $24 |
| ADMA Biomanufacturing LLC | 1 | $19 |
| Hikma Pharmaceuticals USA | 1 | $18 |
| Alk-abello, Inc | 1 | $18 |
| Merck | 1 | $17 |
| Boehringer Ingelheim | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ImmunoCAP$150
How this compares
$3,614 in reported general payments places this provider in the 45th percentile of 26 allergy & immunology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 40 | $29,318 |
| Breo ElliptaFluticasone/Vilanterol | 70 | $27,671 |
| SymbicortBudesonide/Formoterol Fumarate | 30 | $6,979 |
| Azelastine Hcl | 160 | $4,358 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 36 | $4,201 |
| Epinephrine | 21 | $4,192 |
| Incruse ElliptaUmeclidinium Bromide | 12 | $4,178 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 26 | $3,839 |
| AlvescoCiclesonide | 14 | $3,729 |
| Arnuity ElliptaFluticasone Furoate | 14 | $2,735 |
| Wixela InhubFluticasone Propion/Salmeterol | 12 | $2,681 |
| Ipratropium Bromide | 41 | $2,067 |
| Montelukast Sodium | 102 | $1,201 |
| Fluticasone Propionate | 91 | $970 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 31 | $678 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $920 | $63,902136 claims |
| AstraZenecaSymbicort | $205 | $6,97930 claims |
| Hikma Pharmaceuticals USAEpinephrine | $18 | $4,19221 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 26 allergy & immunology providers in Arkansas.
Other allergy & immunology in Little Rock
- Blake ScheerLittle Rock$81K
- Jim IngramLittle Rock$62K
- Karl SitzLittle Rock$19K
- Stacy GriffinLittle Rock$10K
- Ashley StonerLittle Rock$7K
- Kim JacksonLittle Rock$6K
- Adam PriceLittle Rock$4K
- Gene FranceLittle Rock$2K
- Joshua KennedyLittle Rock$2K
- Meredith DilleyLittle Rock$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.